1-3 of 3
Michael Carroll, MD
Close
Sort by
Journal Articles

Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.

Paul G. Richardson, MD, Asher Chanan-Khan, MD, Sagar Lonial, MD, Amrita Krishman, MD, Michael Carroll, MD, G.F. Cropp, MS, K. Kersey, MS, M. Abitar, MD, R.G. Johnson, MD, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2007) 110 (11): 1165.
https://doi.org/10.1182/blood.V110.11.1165.1165
Published: 2007
Journal Articles

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Paul Richardson, MD, Asher Alban Chanan-Khan, MD, Sagar Lonial, MD, Amrita Krishnan, MD, Melissa Alsina, MD, Michael Carroll, MD, Karen Adler, G. Cropp, C. Mitsiades, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS, Kenneth C. Anderson, MD
Journal: Blood
Blood (2006) 108 (11): 406.
https://doi.org/10.1182/blood.V108.11.406.406
Published: 2006
Journal Articles

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Francis J. Giles, MD, Michael Carroll, MD, Alan List, MD, Alessandra Ferrajoli, MD, Deborah Thomas, MD, Jorge Cortes, MD, Eric Feldman, MD, Gail Roboz, MD
Journal: Blood
Blood (2006) 108 (11): 4920.
https://doi.org/10.1182/blood.V108.11.4920.4920
Published: 2006